

MARKET REPORT



Ulcerative Colitis Global Clinical Trials Review, H2, 2016

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative Colitis Global Clinical Trials Review, H2, 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative Colitis Global Clinical Trials Review, H2, 2016

Ulcerative Colitis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Ulcerative Colitis Global Clinical Trials Review, H2, 2016" provides an overview of Ulcerative Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Ulcerative Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
 - Helps in identifying prominent locations for conducting clinical trials which saves time and cost
 - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- <https://www.bioportfolio.co.uk/product/27440>
bioportfolio97@gmail.com to order

- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additional Details

Publisher : Global Data

Reference : GDHC3742CTIDB

Number of Pages : 497

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Ulcerative Colitis Global Clinical Trials Review, H2, 2016

- Table of ContentsTable of Contents 2List of Tables 3List of Figures 4Report Guidance 5Clinical Trials by Region 6Clinical Trials and Average Enrollment by Country 7Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9Top Five Countries Contributing to Clinical Trials in Europe 10Top Countries Contributing to Clinical Trials in North America 11Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12Top Five Countries Contributing to Clinical Trials in Central and South America 13Clinical Trials by G7 Countries: Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials 14Clinical Trials by Phase in G7 Countries 15Clinical Trials in G7 Countries by Trial Status 16Clinical Trials by E7 Countries: Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials 17Clinical Trials by Phase in E7 Countries 18Clinical Trials in E7 Countries by Trial Status 19Clinical Trials by Phase 20In Progress Trials by Phase 21Clinical Trials by Trial Status 22Clinical Trials by End Point Status 23Subjects Recruited Over a Period of Time 24Clinical Trials by Sponsor Type 25Prominent Sponsors 26Top Companies Participating in Ulcerative Colitis Therapeutics Clinical Trials 27Prominent Drugs 29Latest Clinical Trials News on Ulcerative Colitis 30Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 30Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 30Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis 31Jul 28, 2016: Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ (Tofacitinib Citrate) in Ulcerative Colitis 32Jul 13, 2016: InDex Pharmaceuticals publishes results from COLLECT study 33Clinical Trial Profile Snapshots 34Appendix 494Abbreviations 494Definitions 494Research Methodology 495Secondary Research 495About GlobalData 496Contact Us 496Disclaimer 496Source 497

List Of Tables in Ulcerative Colitis Global Clinical Trials Review, H2, 2016

List of Tables

- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Region, 2016* 6
- Ulcerative Colitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
- Ulcerative Colitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
- Ulcerative Colitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
- Ulcerative Colitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
- Ulcerative Colitis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
- Ulcerative Colitis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
- Ulcerative Colitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
- Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
- Ulcerative Colitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
- Ulcerative Colitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
- Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
- Ulcerative Colitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
- Ulcerative Colitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
- Ulcerative Colitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
- Ulcerative Colitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
- Ulcerative Colitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List Of Figures, Charts and Diagrams in Ulcerative Colitis Global Clinical Trials Review, H2, 2016

List of Figures

- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
- Ulcerative Colitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
- Ulcerative Colitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
- Ulcerative Colitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
- Ulcerative Colitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
- Ulcerative Colitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
- Ulcerative Colitis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
- Ulcerative Colitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
- Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 14
- Ulcerative Colitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
- Ulcerative Colitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
- Proportion of Ulcerative Colitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 17
- Ulcerative Colitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
- Ulcerative Colitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
- Ulcerative Colitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
- Ulcerative Colitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
- Ulcerative Colitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
- Ulcerative Colitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
- Ulcerative Colitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
- GlobalData Methodology 495

How to Buy...

Ulcerative Colitis Global Clinical Trials Review, H2, 2016

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27440>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2125** | Single User Price
- \$4250** | Site License Price
- \$6375** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.